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Background: The question of a genetic contribution to the higher prevalence and incidence of end stage kidney
disease (ESKD) among African Americans (AA) remained unresolved, until recent findings using admixture mapping
pointed to the association of a genomic locus on chromosome 22 with this disease phenotype. In the current
study we utilize this example to demonstrate the utility of applying a multi-step admixture mapping approach.
Methods: A multi-step case only admixture mapping study, consisted of the following steps was designed: 1)
Assembly of the sample dataset (ESKD AA); 2) Design of the estimated mutual information ancestry informative
markers (n = 2016) screening panel 3); Genotyping the sample set whose size was determined by a power analysis
(n = 576) appropriate for the initial screening panel; 4) Inference of local ancestry for each individual and
identification of regions with increased AA ancestry using two different ancestry inference statistical approaches; 5)
Enrichment of the initial screening panel; 6) Power analysis of the enriched panel 7) Genotyping of additional
samples. 8) Re-analysis of the genotyping results to identify a genetic risk locus.
Results: The initial screening phase yielded a significant peak using the ADMIXMAP ancestry inference program
applying case only statistics. Subgroup analysis of 299 ESKD patients with no history of diabetes yielded peaks
using both the ANCESTRYMAP and ADMIXMAP ancestry inference programs. The significant peak was found on
chromosome 22. Genotyping of additional ancestry informative markers on chromosome 22 that took into account
linkage disequilibrium in the ancestral populations, and the addition of samples increased the statistical significance
of the finding.
Conclusions: A multi-step admixture mapping analysis of AA ESKD patients replicated the finding of a candidate
risk locus on chromosome 22, contributing to the heightened susceptibility of African Americans to develop non-
diabetic ESKD, and underscores the importance of using mutual information and multiple ancestry inference
approaches to achieve a robust analysis, using relatively small datasets of “affected” only individuals. The current
study suggests solutions to some limitations of existing admixture mapping methodologies, such as considerations
regarding the distribution of ancestry information along the genome and its effects on power calculations and
sample size.
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Chronic kidney disease (CKD) encompasses a spectrum
of different pathophysiologic processes associated with
abnormal kidney function, and a progressive decline in
glomerular filtration rate (GFR), culminating in a degree
of irreversible loss of GFR (reduction to < 15 ml/min
per 1.73 m
2) necessitating renal replacement therapy
(dialysis or transplantation) in order to sustain life
(Stage V Chronic Kidney Disease, also known as End
Stage Kidney Disease or ESKD). Even in those constitu-
encies where such renal replacement modalities are
available, quality of life and lifespan are dramatically
reduced, and in many regions of the world where renal
replacement therapy is not available, ESKD is fatal [1].
It has long been recognized that there are striking eth-
nic differences in the incidence and prevalence rates of
ESKD [2]. In the United States (US) African Americans
(AA), have the highest incidence and prevalence of
ESKD [3]. Previous studies have concluded that the
higher prevalence of both diabetes and hypertension,
which have been considered the two leading etiologies
of CKD, among AA are not sufficient to explain this
increased risk [4,5]. Other studies have indeed ques-
tioned whether chronic hypertension is a cause of CKD
in AA, or rather a consequence of other forms of pri-
mary kidney disease [6]. Other epidemiologic studies
have concluded that differences in conventional clinical,
socio-demographic, or lifestyle factors, although impor-
tant, are insufficient to account satisfactorily for the
excess risk of ESKD among AA [7,8]. Adjustment for
the various risk factors associated with kidney disease
led to an estimated 1.87 relative risk of ESKD among
AA compared to Caucasian males [7]. ESKD is most
probably a multi-factorial disease phenotype affected by
both genetic and environmental process. Moreover, with
respect to the genetic contribution, as is the case for
many common complex adult onset disorders, it is likely
that common variants with variable penetrance at multi-
ple genetic loci, each with modest contribution, might
contribute to the disease phenotype and susceptibility to
ESKD [9]. In previous studies, polymorphisms in several
genes such as the plasma kallikrein gene and the human
homologue of the rodent renal failure 1 gene have
demonstrated both linkage and association with ESKD
in the AA population [10-12]. Most strikingly, two stu-
dies [13,14] reported that the genetic locus MYH9 on
chromosome 22, explains much of the increase in non-
diabetic ESKD among AA, but made no apparent con-
tribution to the increased susceptibility of AA to ESKD
related to diabetic kidney disease.
Both of these previous studies utilized admixture
mapping, (AM), as the population-based genome wide
mapping tool. AM makes use of the relatively recent
admixture in the Americas of individuals of African
and European ancestry [15,16], and is based on the
assumption that the low rates of gene flow prior to
admixture of the two ancestral populations generated
pre-admixture allele frequency differences at many loci
across the entire genome [17]. When two such pre-
viously genetically differentiated populations admix,
extensive gamete phase imbalance or linkage disequili-
brium is generated in the admixed population. The
gene flow that takes place during admixture results in
the temporary generation of long stretches of DNA
sequence (haplotype blocks) in which polymorphic loci
are in admixture linkage disequilibrium. The AM
method is applied in three steps. First, either cases, or
both cases and controls are genotyped via a panel of
ancestry informative markers (AIMs). Second, the
ancestry of each sampled individual is inferred along
the entire genome. Finally, the genome of affected
individuals is scanned in search for a region that
shows an elevated frequency of the ancestry with a
higher risk for the studied phenotype. AM has a statis-
tical power that is similar to association mapping to
detect disease-associated variants that differ markedly
in frequency between populations [18]. In AM, the
ability to detect haplotypes that contain a disease-asso-
ciated variant for a specific complex disease is maxi-
m i z e db ya n a l y z i n gt h em a r k e r st h a ta r em o s t
divergent between the ancestral populations of the
admixed group, namely Ancestry Informative Markers
(AIMs).
Despite the reproducibility of the locus on chromo-
some 22 as a candidate region for the increased risk of
African Americans (Nelson et. al 2010), and Hispanic
Americans (Behar et al 2010) to develop ESKD, the cau-
sative mutation accounting for the AM signal was not
identified within the MYH9 gene (Nelson et al 2010). In
the current study we utilize an information-theory based
measure which we have recently developed [19], desig-
nated as “expected mutual information” (EMI) and
apply a simple and effective algorithm for the selection
of panels that strives to maximize the EMI score. EMI
computes the impact of a set of markers on the ability
to infer ancestry at each chromosomal location. Using
these tools we present here an hierarchical multi-step
AM approach which validates the previously reported
chromosome 22 locus associated with increased risk for
non-diabetic ESKD among AA, and propose that this
approach can be applied more widely to extend AM to
other complex disease phenotypes with moderate differ-
ences in prevalence and incidence rates between ances-
tral populations, even with small to moderate size
samples sets of (fewer than several hundred individuals)
of affected only individuals.
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Study Design
A multi-step case only AM study was designed, suitable
to the available sample set and genomic association
question. Study design consisted of the following steps:
1) Assembly of the sample dataset; 2) Design of the
AIMs screening panel 3); Genotyping a sample set
whose size is determined by a power analysis appropri-
ate for the initial screening panel of genome wide ances-
try informative SNP markers; 4) Inference of local
ancestry for each individual and identification of regions
with increased AA ancestry using two different ancestry
inference statistical approaches; 5) Enrichment of the
initial screening panel with additional AIMs markers
located on the chromosome of interest identified in step
4; 6) Power analysis of the directed enriched panel 7)
Genotyping of additional samples using the enriched
panel. 8) Re-analysis of the genotyping results to identify
a genetic risk locus.
1) Assembly of the sample dataset
The patient group included all consenting ESKD
patients recruited from DaVita Cabrini and Fresenius
dialysis facilities in New York (NY) City. Informed con-
sent was obtained from all patients and a questionnaire
completed. The entire clinical research protocol was
approved by the IRB of the participating institutions,
Ancestry was designated by self identification, the birth-
places of each subject and both parents were also
recorded. Some of the samples in the current study,
were also included as part of a comparative analysis in a
s t u d yw h i c hr e p o r t e dt h er o l eo fM Y H 9a l l e l e si nt h e
risk for ESKD among Hispanic Americans [20]. Self
identified ancestry was shown in previous studies to be
a reliable measure of ancestry [21]. Detailed characteris-
tics of the cohort population are provided in Table 1.
For the screening genotyping step the inclusion criteria
were: self identified AA ESKD patients, with place of
birth of the subject and both parents in the U.S. Indivi-
duals with the following diagnoses were excluded: etiol-
ogy of ESKD due to polycystic kidney disease,
obstructive uropathy, amyloidosis, cancer related renal
failure. The etiology of renal disease was obtained from
the patients’ medical records as recorded in the hemo-
dialysis facilities. Diabetes related ESKD was defined as
self-reported and/or prevalent treatment with insulin
and/or oral hypoglycemic agents or as documented in
the written medical record. Age of onset of first dialysis
was also obtained from the medical record. Additional
samples for the enrichment step were randomly chosen
self identified AA ESKD patients who also met foregoing
inclusion and exclusion criteria.
2) Design of the AIMs screening panel
As a platform for the AIMs screening panel we used a
panel of 2000 AIMs validated by Tian et al [22] (Tian
Panel). In order to accommodate this panel to the Illu-
mina GoldenGate bead array technology a validation
process for the Illumina GoldenGate assay was utilized,
in which 1600 AIMs were predicted to yield high geno-
typing rates. In order to enrich this 1600 AIMs panel
we developed a novel computational platform, for selec-
tion of ancestry informative markers, using an informa-
tion-theory based measure, called Expected Mutual
Information (EMI), as previously reported [19]. EMI
computes the impact of a set of markers on the ability
to infer ancestry at each chromosomal location. We
further developed a simple and effective algorithm for
the selection of panels that strives to maximize the EMI
score [19]. Ancestral population allele counts for admix-
ture analysis were compiled from HapMap [23]. Using
the EMI based enrichment approach we validated an
additional 416 Illumina GoldenGate AIMs markers, thus
generating the 2016 AIMs screening panel, (Additional
File 1). All physical positions and SNPs details reported
in the current study were based on NCBI genome build
36, and dbSNP build 127.
3) Power analysis and genotyping
In order to determine the sample size needed for the
case only AM screening step we conducted a set of
simulations using the EMI based screening panel, using
ANCESTRYMAP, and compared its performance to the
Tian panel.
A multiplicative risk model parameterized by several
ethnicity relative risk values (ERR) was used. We gener-
ated samples of admixed-individual genotypes for a case
only analysis using ANCESTRYMAP. For each run, a
single marker location on chromosome 4 and 22 was
designated as the disease-predisposition locus. In order
to evaluate the performance of the EMI based screening
panel across the entire chromosome, a set of disease-
predisposition loci were chosen using a resolution of
four markers per Cm; consequently, 627 and 186 uni-
formly selected locations across chromosome 4 and 22
(respectively) were used in the power experiments. A
range of ethnicity relative risk (ERR) ratios, between 0.4
and .0.8, were set as the disease model parameters, all
assuming that the African population exhibits the higher
Table 1 Clinical Characteristics of the cohort population
Screening Panel Enrichment Panel Total
Males 282 (49%) 151 433
Females 294 (51%) 106 400
Age 60 ± 13 61 ± 13 61 ± 13
Years on Hemodialysis 4.2 ± 3.9 4.3 ± 3.8 4.3 ± 3.9
Diabetes 277 (48%) 155 (60%) 432
No diabetes 299 (52%) 102 (40%) 401
Total 576 257 833
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runs which identified the putative disease loci. We have
tested the power to detect a disease loci with genome
log-factor >2 using ANCESTRYMAP. The power of the
current screening panel was compared to the 2000
AIMs panel which appeared in Tian et.al [22], and
p values were calculated using the Chi square test.
According to the power simulations for an ethnicity
risk ratio of 0.6 only 576 AA ESKD patients were
needed in order to reach a power of 80%, using the EMI
based screening panel, and assuming a homogeneous
phenotype in terms of the risk locus. Accordingly 576
self declared AA ESKD patients were genotyped for the
2016 AIMs screening panel using the GoldenGate assay.
Only SNPs with genotype call rates of 85% or more
were included in the analysis phase.
4) Inference of local ancestry for each individual and
identification of regions with increased African ancestry
using two different ancestry inference statistical approaches
Both ANCESTRYMAP [24] and ADMIXMAP [25] pro-
grams were used to assess individual ancestry proportions
and to scan the genome for regions of African ancestry
that differ significantly from the genome average. For
ANCESTRYMAP, risk models ranging from 0.25- to 4-
fold risk per African chromosome were assessed. We eval-
uated significance by LGS scores reported by ANCESTRY-
MAP. ANCESTRYMAP was used with the parameters of
100 for burn-in and 200 for follow-on iterations for all
Markov chain-Monte Carlo runs as recommended.
ANCESTRYMAP also calculated a LOD score for gen-
ome-wide significance; a score greater than 1.0 was con-
sidered as a candidate region and a score greater than 2.0
was considered significant [24].
ADMIXMAP: 500 iterations were used for burn-in of
the Markov chain. The tests for linkage provided in
ADMIXMAP [25] are score tests based on the missing-
data likelihood. U is evaluated as the posterior expecta-
tion of the realized score, and the observed information
V is calculated by subtracting the missing information
(posterior variance of the realized score) from the com-
plete information (posterior expectation of the realized
information). The models from ADMIXMAP calculate
results in terms of standard normal Z statistics and p
values. In this study we report the minus log base 10 of
the affected only p values from ADMIXMAP final
report.
5) Directed enrichment of the screening panel
The Results of step 5 were reviewed, and regions for
further investigation were chosen according the follow-
ing criteria: 1) LGS Local ≥ 2: The log likelihood of the
LGS score obtained by averaging over all the markers
on a chromosome as computed by ANCESTRYMAP. 2)
In ADMIXMAP, p value ≤ 10
-3 for at least 2 consecu-
tive AIMs within a range of 4 Cm.
Chromosomes with screening AM loci which met the
foregoing criteria were further genotyped using an
enriched AIMs panel, selected using the EMI algorithm.
As indicated in the Results section - the chromosome of
interest to which the AIMs enrichment markers were
added is chromosome 22, based on the analysis of the
genome wide screening marker panel. The enrichment
process excluded AIMs that had already been genotyped
in the non-enriched EMI panel. A total of an additional
39 AIMs were available using this approach for chromo-
some 22 to generate the enriched AIMs marker panel
(Additional File 2). All physical positions and SNPs
details reported in the current study were based on
NCBI genome build 36, and dbSNP build 127.
6) Power Analysis of the directed enriched panel
The same methodology for power analysis as step 3 was
used in order to assess the power and sample size
needed in order to validate the chromosome 22 preli-
minary signal. In the second step power analysis we
have used the enriched screening panel (78 AIMs on
chromosome 22) together with the AIMs of chromo-
some 1 in order to evaluate individual ancestry more
accurately. Accordingly for an ethnicity risk ratio of 0.6
an additional 240 AA ESKD patients were needed in
order to reach a power of 80%, using the EMI based
enriched panel for chromosome 22. It should be noted
that at the time of the second step power analysis, the
heterogeneity of the sample set into two disease cate-
gories (diabetic and non-diabetic) was not yet known
and therefore was not included in the power analysis.
7) Genotyping of additional samples using the directed
enriched panel
An additional 257 Self identified AAs with ESKD (155
with diabetes and 102 without diabetes) were genotyped
using the directed enriched panel together with the 576
samples, which had undergone genome wide genotyping.
8) Re-analysis of the genotyping results to identify a
genetic risk locus
The results were reanalyzed using both ADMIXMAP
and ANCESTRYMAP, exactly as described for Step 5
above. A statistically significant locus was considered as
a locus with LGS >5 using ANCESTRYMAP, and a -
LOG (P) > 5 using ADMIXMAP for at least two conse-
cutive SNPs. In order to take into consideration the
effect of LD among the ancestral populations on the
results, AIMs which were 50 kB or less close to each
other were omitted (Additional File 2).
Results
Power of the screening panel
We first sought to assess the added power conferred by
addition of EMI markers to an existing AM single
nucleotide polymorphism (SNP) panel [22], using mar-
kers on two chromosomes of different length and with
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available AIMs panels - namely, chromosomes 4 and 22.
Such power analysis for chromosome 4 shows that for a
sample set of 576 ESKD patients, and an ethnicity rela-
tive risk (ERR) of 0.5 using the EMI enriched screening
panel yielded a power of 0.86 in comparison to 0.78
using the non-enriched panel (p < 0.0001). For other
ERRs models, our analysis showed that the EMI
enriched screening panel had significantly higher statisti-
cal power in comparison to a screening panel with simi-
lar AIMs density. The results for chromosome 22
demonstrate the same trend, albeit with a reduced
power (Figure 1a).
An ANOVA analysis of the Fisher information content
(FIC), as provided in Tian et al [22] for the entire panel
of 2000 SNPs therein demonstrated variability in the
information content for the various chromosomes
(Additional File 3). Accordingly, we compared the distri-
bution of FIC and EMI scores over the entire EMI
enriched screening panel for all chromosomes (Addi-
tional File 4). The lowest mean EMI and FIC scores
were observed for chromosomes 6, 18, 19, and 22, and
we further observed variability at chromosome ends. We
then calculated the probability for distribution differ-
ences among FIC values for various chromosomes using
the Kolomogorov-Smirnov test. The results for chromo-
some 22 (Additional File 5) demonstrated a significant dif-
ference in the distribution of FIC values for chromosome
22 in comparison to chromosomes:1,4,9,13,14,15,20, and
X. Chromosomes 18 and 19 showed even more significant
distribution differences in comparison to most chromo-
somes (data not shown). Chromosome 13, 20 and X
showed significantly higher mean EMI and FIC score
values, in comparison to other chromosomes (Supp. Fig-
ure1). X chromosome variation marker analysis, generally
shows greater differentiation among human populations
than autosomes, related to the difference in effective popu-
lation size, and as reflected by gene flow and or drift pat-
terns [26]. Inclusion of X chromosome markers, can
possibly introduce a confounding effect of differential gen-
der proportion in the founding and the admixed popula-
tions. Therefore, the results of X chromosome admixture
mapping are not included in the current study.
Since previous studies [19,22,27] have demonstrated a
correlation between informativeness of SNPs and the
power to detect susceptibility loci using AM, the varia-
bility in FIC and EMI score distribution along the gen-
ome might explain the large differences in ancestry
inference power among chromosomal loci - such as
observed for chromosomes 4 and 22.
Screening panel results
Following the hierarchical approach outlined in Methods
- we first applied AM analysis using the screening panel,
to the entire sample set (576 ESKD AAs) using ANCES-
TRYMAP. No candidate loci were observed according
to the stepwise criteria for proceeding to peak choice, as
outlined in Methods, namely a locus genome statistic
(LGS) local ≥ 2 (Figure 2). In contrast, three chromoso-
mal candidate loci were observed according to the cri-
teria of a p value ≤ 10
-3 for at least 2 consecutive AIMs
in a range of 4 centimorgans (Cm) using ADMIXMAP -
namely chromosomes 5 and 22 (Table 2). Next, we
repeated the analysis using both ANCESTRYMAP and
ADMIXMAP after subdividing the sample set based on
reported aetiology of ESKD into diabetic (n = 277) and
non-diabetic (n = 299) categories (Table 1). Despite the
reduction in sample size resulting from this subdivision,
ANCESTRYMAP revealed peaks located on two chro-
mosomes (15 and 22) (Figure 2). Analysis of this same
non-diabetic sample subset using ADMIXMAP, revealed
Figure 1 Power analysis of the screening panel.F o rt h ep o w e r
analysis of the screening panel, admixed-individual genotypes for a
case only analysis using ANCESTRYMAP were simulated. A set of
disease-predisposition loci were chosen using a resolution of four
markers per Cm. A range of ethnicity relative risk (ERR) ratios,
between 0.4 and .0.8, were set as the disease model parameters.
Power was measured as the proportion of ANCESTRYMAP runs
which identified the putative disease loci with genome log-factor
>2. The power of the screening panel was compared to the 2000
AIMs panel which appeared in Tian et.al [22].
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mosome 22 demonstrated a peak for the non-diabetic
subset using both analytic approaches (see step 5 in
Methods stepwise criteria). No peaks were evident for
the n = 277 diabetic samples, using either ANCESTRY-
MAP or ADMIXMAP.
While the screening panel, revealed peaks on chromo-
some 22 using both ANCESTRYMAP and ADMIXMAP,
it should be noted that these chromosome 22 peaks did
not reach significance thresholds for disease risk associa-
tion (Figure 3) for the sample sets utilized, thus prompt-
ing enrichment of the panel as the next step.
Enrichment of the screening panel
39 additional SNPs (chosen based on the EMI algorithm
[19]) on chromosome 22 (Sup. Table 1) were added to
the screening panel, and are designated as the enriched
panel. Furthermore, since the screening panel results
revealed non-significant peaks only for the relatively
small non-diabetic subset, and since power analysis indi-
cated the need for a greater samples size, an additional
102 non-diabetic samples were added (Table 1).
A ss h o w ni nF i g u r e4a n dS u p p .T a b l e2 ,a n a l y s i s
using ADMIXMAP revealed the significant peaks
(- LOG (P) > 5) at several loci along the chromosome,
including the region between rs7285549 to rs2213758
(- LOG (P) > 10) and the region between rs3752596 to
rs2076084. In contrast, the LGS scores for the peaks
obtained using ANCESTRYMAP at corresponding
regions rs165824 to rs8138979 and rs3752596 to
rs2076084 (Figure 4) did not exceed LGS > 5. Previous
analyses have indicated that spurious peaks can arise in
linkage and association studies, including admixture
mapping and can be attributed to LD effects in ancestral
populations. Therefore we reasoned the high density of
markers following enrichment on chromosome 22
should be addressed by utilizing markers limited to an
adjacent spacing of >50 Kb. Analysis using ADMIXMAP
yielded a - LOG (P) score of ~15-16 spanning 7 conse-
cutive SNPs in the region of rs4821667 to rs739016
(Supp. Table 2) (Figure 4). Notably, this region contains
the MYH9 gene, as well as the neighbouring APOL1
gene, more recently shown to contain coding region var-
iants which are candidates for ESKD risk causation
[28,29]. Analysis using ANCESTRYMAP yielded a maxi-
mum LGS score of 4.428 at SNP rs7286127, whose phy-
sical location is 34.8 Mbs, and overlapping the set of
significant SNPs obtained using ADMIXMAP (Figure 4).
The excess of African ancestry associated with the
genomic region on chromosome 22 noted above, is also
presented in Table 3. Furthermore the genome wide
score for disease risk attributed to having one African
ancestry allele is 1.6 and for African ancestry alleles the
risk is 2.6.
Discussion
The AM analysis in the current study confirms the
results of previous studies [13,14] which identified a
genomic region on chromosome 22 conferring increased
genetic risk for AA to develop non-diabetic ESKD. This
finding was recently extended to Hispanic Americans,
whose risk for ESKD is intermediate between that of
Figure 2 Locus genome statistics (LGS) local of the screening
panel. The locus genome statistics (LGS) local as provided by
ANCESTRYMAP for each chromosome using the screening panel
(2016 AIMs) and a total of 576 ESKD AA patients (Blue line) of
whom 299 ESKD patients did not have diabetes mellitus (NonDM)
(Red line).
Table 2 LOG (P) score of candidate loci by ADMIXMAP screening panel
Locus Name Position (Cm) Build 36 Position (Bp) Build 36 Chromosome - LOG (P) All Cases - LOG (P) NonDM
rs6811604 50.57 29549192 4 3.32 0.37
rs3923114 76.42 68362054 5 3.05 0.34
rs7700504 81.30 73347096 5 3.15 0.46
rs16872999 83.74 75235507 5 3.38 0.81
rs7712675 85.80 76174323 5 3.06 0.72
rs12938039 94.49 64732231 17 3.05 0.01
rs7286127 37.43 34828811 22 3.77 3.95
rs5756133 38.16 35023926 22 3.46 3.95
All AIMs with a - LOG (P) greater than 3 are presented, for the all ESKD patients (576 samples) and for the non diabetic only patients (299 samples) Cm -
centimorgans. Bp - base pairs.
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within MYH9 were identified, and proposed to narrow
the region containing a putative disease phenotype cau-
sal mutation initially pointing to the MYH9 gene
[20,30]. Since these initial reports, the gene now thought
to contain the functional causative mutation accounting
for the AM peak is the neighboring APOL1 gene,
encoding the apolipoprotein L-1 protein, with the
MYH9 marker associations being the result of very high
levels of linkage disequilibrium, powerful evolutionary
selection and hitchhiking of the MYH9 variants with
putative APOL1 causative mutation [28,29].
In contrast to the two previously reported AM studies,
our results were obtained using a different and indepen-
dent marker panel, a different and independent patient
sample set, and two different analytic approaches. The
importance of replicating identification of genetic risk
loci for common complex disease susceptibility has been
highlighted as a sine qua non for proceeding with
further mechanistic research for such a locus, and cer-
tainly for genetic counseling and clinical applications. In
the case of AM in particular, it has been recommended
that data should be analyzed using at least two of the
several different available ancestry inference programs
[18]. Failure to replicate has been a common feature in
the search for common variants of candidate genes
affecting the risk of complex diseases [31]. In the case of
ESKD among AA, a long standing controversy existed as
to the relative contribution of societal and demographic
as opposed to genetic factors in the increased risk for
ESKD [32,33]. Furthermore other rationales concerning
the etiology of the higher prevalence of ESKD have been
proposed, such as lower mortality rates of AA ESKD
patients [34]. The current study represents the third
AM study confirming the presence of a genetic suscept-
ibility locus for ESKD in African Americans- and also
confirms that the increased risk conferred by this locus
seems to be restricted to non-diabetic ESKD. In the
sub-group of non-diabetic ESKD AA, the increased
genetic risk conferred by the African ancestry risk allele
Figure 3 Results of the screening panel for chromosome 22 by
ANCESTRYMAP and ADMIXMAP. LGS and - minus LOG Base10(P)
are provided by ANCESTRYMAP and ADMIXMAP respectivly for
various AIMs along chromosome 22. Altogether 39 AIMs on
chromosome 22 were genotyped using the screening panel and a
total of 576 ESKD AA patients (Red line) were genotyped, of whom
299 ESKD patients did not have diabetes mellitus (NonDM) (Blue
line).
Figure 4 Results of the enriched panel by ANCESTRYMAP and
ADMIXMAP for chromosome 22. LGS and minus LOG Base10(P)
are provided by ANCESTRYMAP and ADMIXMAP respectivly for
various AIMs along chromosome 22, using the enriched panel (78
AIMs), (Blue line). The results of the enriched reduced panel (67
AIMs), (Red line) represent the LGS and - LOG (P) after the omission
of AIMs which were sequentially spaced at < 50 kB.
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erozygote and 1.87 increased risk in the epidemiological
studies[7]). Though the locus susceptibility was reprodu-
cible in all 3 studies, the exact location of the risk causa-
tive mutation(s) cannot be inferred from AM studies
alone. Indeed, even the initial candidate gene (MYH9)
implicated in the first two AM studies, has since been
superseded by a more statistically and biologically plau-
sible gene (APOL1), though it has been the AM
approaches which focused attention to the chromosome
22 region containing these genes in the first place
[13,14].
Each of the three studies used a different sample set,
but all of the samples were of African American heri-
tage. The current study also utilized a different AIMs
panel and two different analytical methods, confirming
the utility of AM as an effective mapping approach
using relevant populations and disease phenotypes. The
use of two different analytic approaches also reduces the
risk of false positive results inherent in the methodology
of AM and emanating from the complex patterns of LD
among panel SNPs in ancestral populations. Future
research will be needed in order to validate the genetic
risk conferred by the chromosome 22 loci in other
populations, other stages of CKD, and possibly other
modifier loci, taking into the account the complex herit-
ability and multi-factorial nature of ESKD[35,36]
T h ec u r r e n ts t u d ya l s oh i g h l ights additional points of
more general interest pertaining to AM which might be
of interest and utility in application to other sample sets
and disease states - especially when only small sample
sets or weaker ERRs are involved. Examples could
include the increased susceptibility to systemic lupus
erythematosus (SLE) [37] and the higher incidence of
lupus nephritis among AA SLE patients [38,39], or dis-
eases with reduced prevalence among AA (e.g. HCV
clearance)[40] and psoriasis[41]. In particular, we pro-
pose use of a stepwise hierarchical approach and novel
ancestry panel tools in AM analysis projects where ERR
or sample size may be limiting. Furthermore, we have
used a case only study design, which for a given sample
size and marker set, has been suggested by others to be
more powerful than a case control study design
(reviewed in Montana et.al [42]). However, it should be
noted that such a case only study design, might be more
sensitive to inaccuracies in estimation of specified allele
frequencies. This is less problematic with current builds
of dbSNP, which are based on larger sample sets in
comparison to the SNPs datasets that were available in
earlier admixture mapping studies. Notwithstanding
these reservations, the analysis based on real samples in
the current study, in which the admixture peak and its
genetic loci have been validated in independent studies,
lends further confidence to the predicted power and
accuracy of an appropriately formulated case only study
design.
The results of the power analysis of the non-enriched
screening panel in the current study, demonstrated a
non-homogenous distribution of ancestry information
across the genome (Additional File 3). The main differ-
ences were observed while inspecting the distribution of
ancestry information along several chromosomes, which
exhibited marked differences in the information content
among and along the lengths of chromosomes, generat-
ing a situation in which the mean information content
i sq u i t es t a b l eo v e rt h eg e n o m ea saw h o l e ,b u tw i t h
marked regional differences in the distribution of infor-
mation content in comparison to the genome as a
whole. This was the case for chromosomes 18, 19 and
22 - the latter of which turned out to be the chromo-
some harbouring the genetic susceptibility locus of
interest. While fortuitous - this turned out to be infor-
mative in the formulation of an effective step wise
approach of potential general utility. Thus the heteroge-
neity of information content, involving chromosome 22,
likely explains the differences in the power of the non-
enriched screening panel to identify true positive loci
along chromosome 22 (Figure 1). Presumably the
regions on chromosome 22 with lower information con-
tent yield lower accuracy in the ancestry inference and
therefore reduced the capacity to identify a disease risk
locus in the power experiments, which were conducted
systematically over all of the chromosomes. This would
be expected to yield a false negative result for a true dis-
ease risk locus on chromosome 22, as was indeed the
case for the actual sample set analysed - which yielded
suggestive peaks according to pre-set criteria as outlined
in Methods, but peaks which did not meet rigorous




Expected African Ancestry Among
AA*
Estimated African Ancestry Among AA ESKD
patients**
% Change in African
Ancestry
rs7286127 0.833 0.923 10.8%
rs5756133 0.865 0.954 10.2%
*Expected loci specific African ancestry was calculated from the African allele frequency as was reported by dbSNP build 127, multiplied by genome average
African ancestry as was reported by ANCESTRYMAP.
**Estimated African ancestry was reported for each locus using ANCESTRYMAP.
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gestive peaks - this limitation was then overcome using
both the EMI enrichment process which strives to maxi-
mize the chromosome-wide information by taking into
account mutual marker information, together with the
power enhancement afforded by the enriched panel and
adjustment of the sample size accordingly.
Since the information content is not homogeneously
distributed over the chromosomes, the relative risk con-
ferred by an associated locus is not known in advance,
leading to the expectation of a shift in the estimated
power. Therefore, we suggest that following the addition
of AIMs, re-analysis of power should be undertaken in
order to estimate the number of samples needed for a
locus of interest which has arisen in a screening panel.
It should be noted that this hierarchical approach, using
an initial genome wide screening panel - could poten-
tially overlook candidate peaks (type II error), which
would then not make it to the step of scrutiny by an
enriched panel on the chromosome or region of interest.
It is reassuring that in the current study - an initial
screening panel of only 2,016 SNPs and what turned out
to be an initial sample set of only 277 relevant (non-dia-
betic ESKD) samples, led to the appropriate next steps,
using ANCESTRYMAP and ADMIXMAP as the initial
ancestry inference programs, which converged on one
shared risk locus.
An additional important lesson from the current study
is the inferential power achieved by combining two dif-
ferent analytic and computational platforms, once geno-
type information is available. Although previous
guidelines for AM methodology recommended the use
of at least 2 analytical approaches [18], most published
AM studies have generally used only one statistical ana-
lysis platform [13,14,43-48]. The study by Nalls et.al
used all three currently available statistical programs
(ADMIXMAP, STRUCTURE, and ANCESTRYMAP),
and concluded that it was difficult to directly compare
the significance values from the three programs, because
each program calculates a different statistic for associa-
tion [49]. In the current study we followed this recom-
mendation and used both ANCESTRYMAP and
ADMIXMAP as statistical platforms. Tian et.al [22] had
previously reported a high rate of false positive results
when using ANCESTRYMAP at chromosomal positions
in complete LD. In contrast, no false-positive peaks
were observed in the same simulations using ADMIX-
MAP. Our goal in the screening panel step of the cur-
rent study was to identify one or more candidate true
positive regions containing a common risk variant.
ANCESTRYMAP was used because of its unique
LGS local score, which can point to a possible associa-
tion for a given chromosome, unlike ADMIXMAP
software which instead provides statistics for
individual markers only. Indeed, in the current study,
ANCESTRYMAP yielded no peaks across all chromo-
somes for the entire sample set, but did yield a candi-
date peak in the non-diabetic subset of samples
(Figure 2, 3), consistent with the previous reports by
Kopp et.et [14] and Kao et.al [13]. A second peak on
chromosome 15 was also evident. The second peak in
ANCESTRYMAP on chromosome 15 was not
observed using ADMIXMAP (Additional File 6). Only
chromosome 22 yielded a candidate locus using both
ANCESTRYMAP and ADMIXMAP. It was this finding
which then prompted the next enrichment step direc-
ted to this locus.
The goals of the enrichment process were to validate
and fine tune the screening panel results, and to narrow
the region. The results of ANCESTRYMAP with its LGS
local parameter yielded two candidate peaks on chromo-
some 22 (Figure 4). Based on the simulation by Tian et.
al [22] we considered the possibility that one of these
peaks might be a false positive result, consequent to the
effect of very high levels of LD in the ancestral popula-
tions. Indeed using ADMIXMAP, it was clearly demon-
strated that the deliberate omission of SNPs with the
highest D’ values in the ancestral populations pointed
only to the peak at nucleotide positions 35-37 Mbs, and
giving a significant association (- LOG (P) > 10) (Figure
4). This result highlights the importance of spacing
SNPs in such a way as to avoid spurious peaks pre-
sumed due to LD interference, which in the case of the
current study required spacing of SNPs at distances
greater than 50 kB. Tian et al [22] used simulations to
suggest that residual LD, even at spacing of 100 kB as in
the screening panel, can yield spurious peaks, using a
case only design and ANCESTRYMAP, but not
ADMIXMAP as the statistical analysis approach. Using
experimental data, and both a screening and enriched
panel, we have been able to verify this effect of residual
LD, which occurs using either ANCESTRYMAP or
ADMIXMAP - but which can be overcome by addition
of appropriately spaced markers so as to avoid presumed
LD interference. It is evident from the current study
that use of ADMIXMAP alone, will not overcome this
effect, as had been suggested based on simulation stu-
dies [22]. Our results support previous observations that
residual LD in the ancestral populations causes false
positive signals[50], thus limiting the density of AIMs
that can be used and highlighting the utility of using
both multiple analytic approaches, as well as selecting
carefully spaced enrichment markers, especially for
moderate risk loci. We can recommend 50 kB as an
empirical lower limit to spacing of AIMS in AM, with
judicious use of more than on analytic approach and
choice of coinciding peaks for the further detailed
search for candidate genes.
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p values obtained from ADMIXMAP, were more signifi-
cant in comparison to those obtained using the ANCES-
TRYMAP LOD scores (Figure 4 reduced panel). One
possible explanation is that ADMIXMAP does not apply
any correction for multiple hypothesis testing [42].
Furthermore as can be observed in Figure 4 ADMIX-
MAP results are greatly influenced by the omission of
dense SNPs (with high LD in ancestral populations),
while the corresponding changes for ANCESTRYMAP
are only moderate. However, we caution that while
highly tenable, we cannot conclude definitively that this
is the source of discordance between ANCESTRY MAP
and ADMIXMAP, since each of these analytical pro-
grams calculates a different statistic for LD.
Conclusions
A multi-step AM analysis of ESKD patients, using a new
patient sample set, and a different SNP marker panel,
replicates the previously reported identification of a
genetic disease phenotype risk locus located on chromo-
some 22, which contributes to the increased risk for
non-diabetic ESKD in AA. In addition, the current study
stresses the importance of using two different statistical
approaches for the analysis of AM. This study also high-
lights the importance of evaluating LD resulting from
marker density - an important factor which yields infla-
tion in significance, which was has also been observed
in other type of linkage and association analysis [50]. An
interesting observation to be further studied is the non-
homogeneous distribution of ancestry information
across the genome and its possible practical utility in
terms of power analysis and AM experiment design.
Additional material
Additional file 1: Expected Mutual Information (EMI) ancestry
informative markers screening panel. The AIMs were chosen
according to EMI enrichment algorithm. 2016 markers were chosen.
Additional file 2: Directed enriched panel chromosome 22.
Enrichment of the screening panel was applied to chromosome 22. All
additional AIMs were chosen according to EMI algorithm. 39 additional
AIMs were added. For the sub-analysis of the effect of ancestral LD
markers which were 50 kB apart from each other or less were omitted
from the analysis. In the status column 1 = AIMs from screening panel 2
= AIMs from directed enriched panel. 3 = AIMs from directed enriched
panel which were omiited due to a distance of less than 50 kB from
other markers.
Additional file 3: Distribution of Fisher Information Content (FIC)
along the genome for the 2016 markers of the screening panel.F o r
each chromosome the mean FIC (2 red circles), two standard deviations
of the FIC value (dashed line) and outliers of AIMs with high FIC (red
plus) are presented.
Additional file 4: Distribution of expected mutual information (EMI)
score along the genome for the 2016 markers of the screening
panel. The Y axis for each chromosome represents the EMI score (the
information of a set of markers regarding the ancestry of a chromosomal
position, the X axis represents the genetic position of all AIMs in the
screening panel in Cm according to the Marshfield genetic map.
Additional file 5: Differences in the distribution of FIC values
between chromosome 22 and other chromosomes. For each
chromosome the mean FIC (circles) and the range of FIC (horizontal
lines) are displayed. P values represent differences in the distribution of
FIC as was calculated by pairwise Kolmogorov-Smirnov test.
Additional file 6: Chromosome 15 LGS and - LOG (P) scores of the
screening panel by ANCESTRYMAP and ADMIXMAP respectively.
LGS and - LOG (P) are provided by ANCESTRYMAP and ADMIXMAP
respectivly for AIMs along chromosome 15. Using the screening panel a
total of 576 ESKD AA patients (Red line) were genotyped of whom 299
ESKD patients did not have diabetes mellitus (NonDM) (Blue line).
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